Anpirtoline
chemical compound
Anpirtoline (INNTooltip International Nonproprietary Name; developmental code name D-16949), also known as 2-chloro-6-piperidin-4-ylsulfanylpyridine, is a serotonin receptor modulator which was under development for the treatment of major depressive disorder (MDD) and pain but was never marketed.
Pharmacology
Pharmacodynamics
It is a serotonin 5-HT1B and 5-HT1D receptor agonist, a serotonin 5-HT1A receptor ligand, a serotonin 5-HT3 receptor antagonist, and also binds to the serotonin 5-HT2 receptors with weak affinity. However, it acts preferentially as a serotonin 5-HT1B receptor agonist and is sometimes described as being selective in this action. It causes a decrease in serotonin synthesis and a reduction in aggressive behavior.
The drug is primarily used for research purposes due to its receptor agonist and receptor antagonist properties. Studies involving social instigation, aggression, and other behavioral traits make ample use of the compound.
Chemistry
Anpirtoline is a synthetic compound. The hydrochloride salt appears as a white solid at room temperature and is soluble in water and DMSO. It has a density of 1.27 g/cm3 and a molar mass of 265.20. Structurally, the most notable parts of anpirtoline hydrochloride are two six-membered rings bonded via a sulfur atom. The melting point of anpirtoline hydrochloride is 126-128 °C. The flash point of the compound is 174 °C. Many of Anpirtoline hydrochloride's chemical properties remain unknown or untested.
The public source identifies “Anpirtoline” as chemical compound. This brief keeps that definition visible, then builds a research path around Anpirtoline, chemical and compound.
Why this record matters
A short description can identify a subject without explaining its stakes. For “Anpirtoline”, the useful work is to connect “chemical compound” to the records capable of establishing context and consequence.
Stable identifiers, scientific names and standards terminology offer the best bridge between this overview and specialist evidence. The source revision retrieved here is dated Jan 30, 2026. The linked authority identifier is Q27164702. None of the 0 selected statements returned an explicit reference.
A general summary may omit uncertainty, sample limits or methodological disagreement that is explicit in the technical record. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.
- Current terminology
- Classification context
- Finding cited technical literature
Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.
Three-step research path
- Establish the record: confirm the title “Anpirtoline”, its source revision and the description used here.
- Expand the search: follow Anpirtoline primary sources, Anpirtoline archive and Anpirtoline research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Anpirtoline”?
- Is the terminology current, historical or disputed?
- Has classification or technical consensus changed since the cited source?
Search terms from this dossier
This entry incorporates text from “Anpirtoline” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.